SelSA-1

SelSA-1 is a **selenium-containing derivative of SAHA (suberoylanilide hydroxamic acid)** that functions as an **HDAC (histone deacetylase) inhibitor** with enhanced chemotherapeutic properties. The compound was designed by incorporating selenium into the SAHA molecule structure to combine the epigenetic regulatory capabilities of HDAC inhibition with the anti-tumorigenic properties of selenium. SelSA-1 demonstrates **improved efficacy and safety profiles compared to its parent compound SAHA**, showing lower IC50 values in cancer cell lines while maintaining better safety margins in normal cells. The compound exerts its anti-cancer effects through **redox modulation of multiple epigenetic and apoptotic pathways**, inducing oxidative stress in cancer cells while promoting resolution of inflammation. SelSA-1 has been primarily studied in preclinical models of **colorectal cancer**, particularly in colitis-associated cancer (CAC) models, where it demonstrated superior reduction in tumor burden, incidence, and inflammatory markers compared to SAHA.

Other names

Selenium analog of SAHA